Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSLG 100754 is a ligand of retinoid X receptor (RXR) that modulates the activity of RXR dimers. It acts as an antagonist towards RXR homodimers but as an agonist of heterodimers consisting of RXR and retinoic acid receptor (RAR) or PPARs.1,2,3 LG 100754, at 1 µM, is a weak agonist of RXR-PPARγ but strongly enhances signaling through the heterodimer in response to PPARγ ligands, including rosiglitazone (Item No. 71740) and 15-deoxy-Δ12,14-prostaglandin J2 (Item No. 18570).4 Through this action, LG 100754 decreases glucose levels and relieves insulin resistance in mice.5,4
WARNING This product is not for human or veterinary use.
1. Existence of retinoic acid-
2. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383(6599), 450-453 (1996).
3. The phantom ligand effect: Allosteric control of transcription by the retinoid X receptor. Genes Dev. 11(3), 299-308 (1997).
4. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-
5. The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol. Endocrinol. 15(8), 1360-1369 (2001).